Transcranial Magnetic Stimulation (TMS)

TMS (specifically left prefrontal rTMS) is covered for adults with severe Major Depressive Disorder who meet evidence-based criteria: inadequate response or intolerance to adequate trials of psychopharmacologic agents (from at least two classes as applicable), a prior adequate psychotherapy trial without improvement, and an order by an experienced psychiatrist with direct physician supervision. TMS is contraindicated in patients with seizure disorders, current psychotic symptoms, certain neurological conditions, or implanted magnetic-sensitive devices within 30 cm of the coil; all other uses are investigational and not covered. Retreatment is permitted only for patients who met initial criteria and previously responded (>50% improvement) and subsequently relapsed.

"TMS may be covered when prescribed and administered by a licensed physician who is trained and experienced in repetitive transcranial magnetic stimulation and provides direct supervision during out..."